Citations

Institution: Mayo Clinic Clear

Showing 10 of 108152 citations.

Age and Comorbidities May Affect the Relationship Between Pulse Pressure and Adverse Outcomes
Kalantari, Kambiz , Schwartz, Gary L.

American Journal of Hypertension | November 18, 2024 | Volume: 38 | Issue: 2 | Pages: 97-99

10.1093/ajh/hpae145 | PMID 39555591 Get It

Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial
Judge, Daniel P. , Gillmore, Julian D. , Ambardekar, Amrut V. , Cappelli, Francesco , Fontana, Marianna , Grodin, Justin L. , Grogan, Martha , Hanna, Mazen, Masri, Ahmad , Nativi-Nicolau, José , Sarswat, Nitasha , Shah, Keyur, Cao, Xiaofan, Wang, Kevin , Tamby, Jean‐François, Katz, Leonid , Sinha, Uma, Fox, Jonathan C. , Maurer, Mathew S. , Alexander, Kevin M , Ambardekar, Amrut V , Cappelli, Francesco , Fontana, Marianna , Garcia-Pavia, Pablo , Grodin, Justin L , Grogan, Martha , Masri, Ahmad , Nativi-Nicolau, Jose , Obici, Laura , Sarswat, Nitasha , Soman, Prem , Lystig, Ted , Fox, Jonathan C , Maurer, Mathew S , Gillmore, Julian D , Judge, Daniel P , Hanna, Mazen, Obici, Laura , Poulsen, Steen Hvitfeldt , Pecoraro, Maria Lucia

Circulation | November 18, 2024 | Volume: 151 | Issue: 9 | Pages: 601-611

10.1161/circulationaha.124.072771 | PMID 39556242 Get It

BACKGROUND: In the phase 3 randomized controlled study ATTRibute-CM (Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy), acoramidis, a transthyretin stabilizer, demonstrated significant efficacy on the primary end point. Participants with transthyretin amyloid cardiomyopathy who completed ATTRibute-CM were invited to enroll in an open-label extension study (OLE). We report the efficacy and safety data of acoramidis in participants who completed ATTRibute-CM and enrolled in the ongoing OLE. METHODS: Participants who previously received acoramidis through month 30 in ATTRibute-CM continued to receive it (continuous acoramidis), and those who received placebo through month 30 were switched to acoramidis (placebo to acoramidis). Participants who received concomitant tafamidis in ATTRibute-CM were required to discontinue it to be eligible to enroll in the OLE. Clinical efficacy outcomes analyzed through month 42 included time to event for all-cause mortality (ACM) or first cardiovascular-related hospitalization (CVH), ACM alone, first CVH alone, ACM or recurrent CVH, change from baseline in NT-proBNP (N-terminal pro-B-type natriuretic peptide), 6-minute walk distance, serum transthyretin, and Kansas City Cardiomyopathy Questionnaire Overall Summary score. Safety outcomes were analyzed through month 42. RESULTS: Overall, 438 of 632 participants in ATTRibute-CM completed treatment, and 389 enrolled in the ongoing OLE (263 continuous acoramidis and 126 placebo to acoramidis). The hazard ratio for ACM or first CVH was 0.57 (95% CI, 0.46–0.72) at month 42 based on a stratified Cox proportional hazards model ( P <0.0001) favoring continuous acoramidis. Similar analyses were performed on ACM alone and first CVH alone, with hazard ratios of 0.64 (95% CI, 0.47–0.88) and 0.53 (95% CI, 0.41–0.69), respectively, at month 42. Treatment effects for NT-proBNP and 6-minute walk distance also favored continuous acoramidis. On initiation of open-label acoramidis in the placebo-to-acoramidis arm, there was a prompt increase in serum transthyretin. Quality of life assessed by Kansas City Cardiomyopathy Questionnaire Overall Summary score was well preserved in continuous-acoramidis participants compared with the placebo-to-acoramidis participants. No new clinically important safety issues were identified in this long-term evaluation. CONCLUSIONS: Early initiation and continuous use of acoramidis in the ATTRibute-CM study through month 42 of the ongoing OLE study were associated with sustained clinical benefits in a contemporary transthyretin amyloid cardiomyopathy cohort, with no clinically important safety issues newly identified. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04988386.
Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results From VALOR-HCM
Desai, Milind Y. , Wolski, Kathy , Owens, Anjali , Geske, Jeffrey B. , Saberi, Sara , Wang, Andrew , Cremer, Paul , Lakdawala, Neal K. , Tower‐Rader, Albree, Naidu, Srihari S. , Smedira, Nicholas G. , Gong, Zhiqun, Mudarris, Lana, Lampl, Kathy, Sehnert, Amy J. , Nissen, Steven E. , Investigators, for the VALOR-HCM, Sherrid, Mark , Cremer, Paul C , Lakdawala, Neal K , Tower-Rader, Albree , Naidu, Srihari S , Smedira, Nicholas G , Schaff, Hartzell , Sehnert, Amy J , Nissen, Steven E , Geske, Jeffrey B , Saberi, Sara , Wang, Andrew , Sherrid, Mark V. , Fermin, David , Schaff, Hartzell V. , Investigators, for the VALOR-HCM

Circulation | November 18, 2024 | Volume: 151 | Issue: 19 | Pages: 1378-1390

10.1161/circulationaha.124.072445 | PMID 39556124 Get It

BACKGROUND: In severely symptomatic patients with obstructive hypertrophic cardiomyopathy (HCM), VALOR-HCM trial (Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy [URL: https://clinicaltrials.gov ; Unique identifier: NCT04349072]) reported that mavacamten reduced the short-term need for septal reduction therapy (SRT). The current report examined the longer-term effect of mavacamten through end of treatment at week 128. METHODS: A double-blind randomized placebo-controlled multicenter trial at 19 sites in the United States included symptomatic obstructive HCM patients referred for SRT (enrollment July 2020 through October 2021). The group initially randomized to mavacamten continued the drug for 128 weeks and the placebo to mavacamten group from week 16 to 128 (112-week exposure). Dose titrations were performed using echocardiographic left ventricular outflow tract gradient and left ventricular ejection fraction measurements. The principal end point was proportion of patients proceeding with SRT or remaining guideline-eligible at week 128. RESULTS: At week 128, 17 of 108 (15.7%) patients in the total study sample met the composite end point (7 underwent SRT, 1 was SRT-eligible, and 9 SRT-status unevaluable). Additionally, 87 of 108 (80.5%) patients demonstrated ≥1 New York Heart Association class improvement by week 128, and 52 of 108 (48.1%) demonstrated ≥2, with a sustained reduction in resting and Valsalva left ventricular outflow tract gradients of 38.2 mm Hg and 59.4 mm Hg, respectively. Ninety-five of 108 (88%) patients transitioned to commercial mavacamten. Overall, 15 of 108 (13.8%) patients (5.41 per 100 patient-years) had an left ventricular ejection fraction <50% (2 with left ventricular ejection fraction ≤30%; 1 death). Of these, 12 of 15 (80%) continued treatment. New-onset atrial fibrillation occurred in 11 (10.2%) patients (4.55 per 100 patient-years). CONCLUSIONS: In severely symptomatic obstructive HCM patients, sustained freedom from SRT was observed at 128 weeks, with nearly 90% patients remaining on long-term mavacamten. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04349072.
Novel HMGA2::COL14A1 Fusion Identified in Xanthogranulomatous Epithelial Tumor/Keratin‐Positive Giant Cell Tumor
Dehner, Carina , Buehler, Darya, Hofich, Christopher, Halling, Kevin C. , Folpe, Andrew L. , Dehner, Carina A

Genes, Chromosomes and Cancer | November 18, 2024 | Volume: 63 | Issue: 11 | Pages: No page available

10.1002/gcc.70010 | PMID 39552601 Get It

ABSTRACTXanthogranulomatous epithelial tumor (XGET)/Keratin‐positive giant cell tumor (KP‐GCT) represents a spectrum of recently described neoplasms characterized by a proliferation of distinctive mononuclear cells expressing keratin within a background of osteoclast‐like giant cells, mixed inflammatory cells, and a variably prominent xanthogranulomatous component. Recent studies demonstrated a recurrent HMGA2::NCOR2 fusion in many cases. We herein describe a case of XGET/KP‐GCT arising in the right femoral head of a 19‐year‐old male harboring a rare novel HMGA2::COL14A1 fusion.
Clinical Evaluation of the NaviNetics Stereotactic System Using Intraoperative Portable Surgical Imaging System in DBS Surgery
Shin, Jee Won , Mandybur, Ian, Hussein, S.H., Klassen, Bryan T. , Gregg, Nick, Miller, Kai J. , Shin, Hojin , Vansickle, David, Lee, Kendall H. , Scheitler, Kristen M. , Sharaf, Basel , Mandybur, Ian, Grewal, Sanjeet S. , Chang, Jin Woo , Oh, Yoonbae

Operative Neurosurgery | November 18, 2024 | Volume: 29 | Issue: 1 | Pages: 93-101

10.1227/ons.0000000000001427 | PMID 39883866 Get It

BACKGROUND AND OBJECTIVES: A typical workflow for deep brain stimulation (DBS) surgery consists of head frame placement, followed by stereotactic computed tomography (CT) or MRI before surgical implantation of the hardware. At some institutions, this workflow is prolonged when the imaging scanner is located far away from the operating room, thereby increasing workflow times by the addition of transport times. Recently, the intraoperative O-arm has been shown to provide accurate image fusion with preoperative CT or MR imaging, suggesting the possibility of obtaining an intraoperative localization scan and postoperative confirmation. In this article, we aim to evaluate the compatibility of the stereotactic frame system with the intraoperative O-arm system regarding lead accuracy and surgical flow. METHODS: A total of 17 patients undergoing DBS surgery for movement disorders were evaluated. One patient underwent both the stereotactic CT and O-arm localization, while 16 patients underwent only intraoperative O-arm localization. Following lead placement, intraoperative O-arm imaging was obtained to evaluate the accuracy of the lead placement. Accuracy was defined as the error measured as the distance from the center of the planned trajectory to the cannula. RESULTS: Less than 0.1 mm difference was found between the O-arm imaging technique and CT image localization of the NaviNetics stereotactic head frame in DBS surgery. Of the 16 patients who underwent the intraoperative O-arm imaging alone, the targets included bilateral ventral intermediate nucleus (16 leads), bilateral globus pallidus internus (4 leads), and subthalamic nucleus (12 leads). The mean ± SD radial error in the probe's eye view was 0.71 ± 0.33 mm for n = 32 leads. No tract hemorrhage was observed. CONCLUSION: Intraoperative O-arm imaging can be used safely and effectively for stereotactic registration and lead placement confirmation with the stereotactic system in both awake and asleep DBS surgery.
Diagnosing and managing gastroparesis - where are we now?
Olson, Caroline G. , Lacy, Brian E. , Olson, Caroline

Expert Review of Gastroenterology & Hepatology | November 18, 2024 | Volume: 18 | Issue: 11 | Pages: 681-683

10.1080/17474124.2024.2431248 | PMID 39552392 Get It

Static Versus Expandable Cages in Minimally Invasive Lateral Lumbar Interbody Fusion
Beyer, Ryan S. , Shooshani, Tara , Batista, Bianca, Fraipont, Genevieve , Pooladzandi, Omead , Pennington, Zach , Pham, Martin H. , Pennington, Zach , Fraipont, Genevieve M , Batista, Bianca, Brown, Nolan J.

Clinical Spine Surgery | November 18, 2024 | Volume: 38 | Issue: 7 | Pages: 326-332

10.1097/bsd.0000000000001737 | PMID 39774441 Get It

Study Design: A meta-analysis approach to a systematic review. Objective: Perform a systematic review to identify all reports directly comparing outcomes of lateral lumbar interbody fusion (LLIF) using static versus expandable interbody cages. Specifically focusing on periprocedural complications, intraoperative morbidity, and fusion outcomes. Summary of Background Data: Minimally invasive surgical techniques, particularly LLIF, have gained popularity for their potential to reduce muscle and soft tissue dissection, leading to faster postoperative recovery. LLIF has been associated with fewer complications compared with open posterior approaches. The introduction of expandable lumbar interbody devices aims to further reduce surgical difficulty and potential complications. However, concerns include a small graft window due to the expansion mechanism and higher costs. Methods: The Web of Science, Scopus, and PubMed databases were systematically queried in accordance with PRISMA guidelines to identify articles comparing outcomes following LLIF using static and expandable interbodies. The Newcastle-Ottawa Scale (NOS) was employed to assess the risk of bias (ROB) in the selected studies. Extracted data underwent effect-size meta-analysis with the PyMARE library, using P<0.05 to define statistical significance. Results: Of the 77 identified articles, 4 studies comprising 283 patients (mean age: 67.1 y, 55.8% female) met the inclusion and exclusion criteria. A total of 150 patients (53%) were treated with static interbodies compared with 133 (47%) receiving expandable interbodies. The groups did not differ significantly with respect to operative time (P=0.59), blood loss (P=0.89), length of stay (P=0.78), subsidence (P=0.49), 24-month mean disc height (P=0.11), 24-month mean ODI (P=0.58), or 24-month mean visual analog scale (VAS) back pain (P=0.81). The expandable group saw a trend toward improved fusion rates (97% vs. 92%, P=0.06). Conclusions: The present meta-analysis suggests the use of expandable (vs. static) interbodies in LLIF surgery may result in similar surgical morbidity, subsidence, and decompression. Further prospective comparative studies are merited to validate these results.
A novel approach to refractory coccydynia: ultrasound- fluoroscopy-guided cryoablation of sacrococcygeal nerve
Mendes–Andrade, Inês , Pagan‐Rosado, Robert , Ferreira‐Silva, Nuno , Hurdle, Mark FB , Hurdle, Mark Friedrich , Ferreira-Silva, Nuno

Pain Management | November 18, 2024 | Volume: 14 | Issue: 10-11 | Pages: 541-547

10.1080/17581869.2024.2430162 | PMID 39552215 Get It

Challenges and outcomes of airway surgery in a post‐war low‐resource setting: A case series from Mekelle, Ethiopia
Eyassu, Daniel G. , Candelo, Estephanía , Asgedom, Brhanu H. , Wallerius, Katherine P. , Twardus, Shaina W., Niermeyer, Weston L. , Green, Katerina J. , Athni, Tejas S. , Wiedermann, Joshua P. , Gomez, Estephania Candelo , Green, Katerina

Laryngoscope Investigative Otolaryngology | November 18, 2024 | Volume: 9 | Issue: 6 | Pages: No page available

10.1002/lio2.70034 | PMID 39559464 Get It

AbstractObjectiveThis study aims to document and analyze the challenges and outcomes of performing complex airway surgery in a low‐resource, post‐war setting in Mekelle, Ethiopia.MethodsThis prospective case series examines clinical data from five patients who underwent airway reconstruction surgeries and one patient who underwent total laryngectomy at Ayder Comprehensive Specialized Hospital in Mekelle. Data included patient demographics, airway stenosis etiology and severity, operative details, postoperative outcomes, complications, and hospital length of stay. Ethical approval was obtained from institutional review boards at Mayo Clinic and Mekelle University.ResultsThe study included six patients aged 9–62 years, with surgeries comprising three cricotracheal resections, two tracheal resections, and one laryngectomy. Three reconstructions were for war‐related injuries. Challenges included power outages during surgeries, limitations in medical supplies and equipment, and inadequate perioperative care. Despite these, three patients requiring tracheostomies were successfully decannulated within a year. However, complications such as restenosis, infections, and the need for reintubation were common.ConclusionAirway surgeries in a low‐resource, post‐war setting face significant hurdles, including perioperative care quality, resource limitations, and infrastructure issues. Successful outcomes require multidisciplinary training tailored to local contexts, investments in hospital infrastructure and reliable electricity, and proper perioperative nutrition. This study highlights the need for comprehensive interventions to improve surgical care in such settings.Level of evidence: IV.
Effects of eplontersen on symptoms of autonomic neuropathy in hereditary transthyretin-mediated amyloidosis: secondary analysis from the NEURO-TTRansform trial
Wixner, Jonas, Adams, David , Polydefkis, Michael , Conceição, Isabel , Dyck, P. James B. , Folkvaljon, Folke, Zhou, Wunan , Chen, Jersey , Viney, Nicholas J. , Kwoh, T. Jesse, Coelho, Teresa , Adams, David , Conceição, Isabel , Gillmore, Julian D , Berk, John L. , Attarian, Shahram , Gillmore, Julian D. , Waddington‐Cruz, Márcia

Amyloid | November 18, 2024 | Volume: 32 | Issue: 1 | Pages: 29-38

10.1080/13506129.2024.2427290 | PMID 39552152 Get It